Literature DB >> 31050313

Lack of choline elevation on proton magnetic resonance spectroscopy in grade I-III gliomas.

Sanjeev Chawla1, Seung-Cheol Lee1, Suyash Mohan1, Sumei Wang1, MacLean Nasrallah2, Arastoo Vossough1,3, Jaroslaw Krejza1,4, Elias R Melhem1,4, S Ali Nabavizadeh1.   

Abstract

Elevated levels of choline are generally emphasized as marker of increased cellularity and cell membrane turnover in gliomas. In this study, we investigated the incidence rate of lack of choline/creatine and choline/water elevation in a population of grade I-III gliomas. A cohort of 41 patients with histopathologically confirmed gliomas underwent multi-voxel proton magnetic resonance spectroscopy on a 3 T magnetic resonance system prior to treatment. Peak areas for choline and myoinositol were measured from all voxels that exhibited hyperintensity on fluid-attenuated inversion recovery images and were normalized to creatine and unsuppressed water from each voxel. The average metabolite/creatine and metabolite/water ratios from these voxels were then computed. Similarly, average metabolite ratios were computed from normal brain parenchyma. Gliomas were considered for lack of choline elevation when choline/creatine and choline/water ratios from neoplastic regions were less than those from normal brain parenchyma regions. Six of 41 (14.6%) grade I-III gliomas showed lack of elevation for choline/creatine and choline/water ratios compared to normal brain parenchyma. Four of these six gliomas also demonstrated elevated levels of myoinositol/creatine ratio. All other gliomas (n = 35) had elevated choline levels from neoplastic regions relative to normal parenchyma. The sensitivity of choline/creatine or choline/water in determining a grade I-III glioma was 85.4%. These findings suggest that a lack of choline/creatine or choline/water elevation may be seen in some gliomas and low choline levels should not prevent us from considering the possibility of a grade I-III glioma.

Entities:  

Keywords:  Glioma; choline; myoinositol; proton magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2019        PMID: 31050313      PMCID: PMC6639641          DOI: 10.1177/1971400919846509

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  34 in total

1.  High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging.

Authors:  Meng Law; Soonmee Cha; Edmond A Knopp; Glyn Johnson; John Arnett; Andrew W Litt
Journal:  Radiology       Date:  2002-03       Impact factor: 11.105

2.  Proton MR spectroscopy in gliomatosis cerebri.

Authors:  J Pyhtinen
Journal:  Neuroradiology       Date:  2000-08       Impact factor: 2.804

3.  Unusual MR spectroscopic imaging pattern of an astrocytoma: lack of elevated choline and high myo-inositol and glycine levels.

Authors:  Ana Londoño; Mauricio Castillo; Diane Armao; Lester Kwock; Kinuko Suzuki
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

4.  MR spectroscopy in gliomatosis cerebri.

Authors:  M Bendszus; M Warmuth-Metz; R Klein; R Burger; C Schichor; J C Tonn; L Solymosi
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

5.  Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma.

Authors:  Damien Galanaud; Olivier Chinot; François Nicoli; Sylviane Confort-Gouny; Yann Le Fur; Maryline Barrie-Attarian; Jean-Philippe Ranjeva; Stéphane Fuentès; Patrick Viout; Dominique Figarella-Branger; Patrick J Cozzone
Journal:  J Neurosurg       Date:  2003-02       Impact factor: 5.115

6.  Correlation of myo-inositol levels and grading of cerebral astrocytomas.

Authors:  M Castillo; J K Smith; L Kwock
Journal:  AJNR Am J Neuroradiol       Date:  2000-10       Impact factor: 3.825

7.  Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy.

Authors:  Kim Vuori; Leena Kankaanranta; Anna-Maija Häkkinen; Eija Gaily; Leena Valanne; Marja-Liisa Granström; Heikki Joensuu; Göran Blomstedt; Anders Paetau; Nina Lundbom
Journal:  Radiology       Date:  2004-01-22       Impact factor: 11.105

8.  Proton MR spectroscopy of gliomatosis cerebri: case report of elevated myoinositol with normal choline levels.

Authors:  Efrat Saraf-Lavi; Brian C Bowen; Pradip M Pattany; Evelyn M L Sklar; James B Murdoch; Carol K Petito
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

9.  Role of proton magnetic resonance spectroscopy in the diagnosis of gliomatosis cerebri: a unique pattern of normal choline but elevated Myo-inositol metabolite levels.

Authors:  Aurea V R Mohana-Borges; Steven G Imbesi; Rosalind Dietrich; John Alksne; Darius K Amjadi
Journal:  J Comput Assist Tomogr       Date:  2004 Jan-Feb       Impact factor: 1.826

10.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.

Authors:  Meng Law; Stanley Yang; Hao Wang; James S Babb; Glyn Johnson; Soonmee Cha; Edmond A Knopp; David Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

View more
  2 in total

Review 1.  Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.

Authors:  Fabrício Guimarães Gonçalves; Sanjeev Chawla; Suyash Mohan
Journal:  J Magn Reson Imaging       Date:  2020-03-19       Impact factor: 4.813

2.  Advanced magnetic resonance imaging and spectroscopy in a case of neurocysticercosis from North America.

Authors:  Sanjeev Chawla; Shadi Asadollahi; Pradeep Kumar Gupta; Kavindra Nath; Steven Brem; Suyash Mohan
Journal:  Neuroradiol J       Date:  2021-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.